Alpha Cognition: Zunveyl growth and new studies strengthen its profile in the Alzheimer's market

Raymond James initiated coverage of the stock of Alpha Cognition (ACOG) on July 10, 2026, with an "Outperform" rating and a price target of $20, backed by the market positioning of the Alzheimer's drug Zunveyl. In June 2026, Alpha Cognition released positive top-line data from the BEACON observational study and began patient recruitment for the Phase 4 study RESOLVE. The first quarter of 2026 showed Zunveyl net revenue of $3.5 million, representing a sequential increase of 40 percent. A focused approach in Alzheimer's treatment Alpha Cognition...